Functions of hereditary immunity and xenogamy in cancer origin and pandemic spread

Sergey N. Rumyantsev

.

DOI: 10.4236/oji.2011.12004                

Abstract

The efficacy of means exploited currently for cancer prevention and treatment appeared to be very low. New insights into the origin of the disease are sorely needed. The present article synthesizes the results from integrative reconsideration of actual data on cancer from the viewpoint of recent developments in pathology, epidemiology, immunology, genetics, and evolution. In contrast to the 80 years old hypothesis of somatic mutative origin of carcinogenesis, the revealed set of evidence showed the origin of cancerous clones is based on inherent constitutional incongruence between the regulators of cell physiology and their targets realized in inherent immunity of cancerous cells to normal regulation of cell replication and tissue growth. The incongruence arises out of both genome mutations which led to interethnic differences in the regulator-receptor structures and intercourse between ethnoses, the regulator-receptor evolution of which has been processed to deal with different ecologic conditions. The current pandemic spread of cancer is brought about growing expansion of interethnic xenogamy favored by growing industrialization, urbanization, globalization, and migration. The proposed hypothesis of genome intrusion in the origin of cancer induces new research ideas and proposals for cancer prevention and therapy.

Keywords

Biodiversity; Cancerous Genealogy; Carcinogenesis; Genomic Mutations; GI-hypothesis; Heterozygosity; Regulator-Receptor system; Self-Reproduction; Somatic Mutations

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Pederson P. (2011) On cancer and people. Science, 332, 423.
[2]	Bauer K.H. (1928) Mutationstheorie der geschswulst- entstehung. Springer, Berlin.
[3]	Marshall E. (2011) Cancer research and the $90 billion metaphor. Science 2011, 331, 1540-1541.
[4]	Anonymous. (2011) 40 years of the war on cancer. Sci- ence, 331, 1540-1541.
[5]	Malakoff D. (2011) Can treatment costs be tamed? Science, 331, 1545-1547.
[6]	Cancer death rates among 50 countries. In: National Cancer Institute, Ed., American Cancer Society, 1992.
[7]	International range of cancer incidence. In: National Cancer Institute, Ed., World Health Organization, 1992.
[8]	Haiman C.A., Chen G.K., Blot W.J., Strom S.S., Berndt S.I., et al. (2011) Characterizing Genetic Risk at Known Prostate Cancer Susceptibility Loci in African Americans. PLoS Genet;7.
[9]	1999-2007 cancer incidence and mortality data. Na- tional Program of Cancer Registries. Betesda, Maryland: USA CDC, 2007.
[10]	Rumyantsev S.N. (2008) Hereditary Immunity: Funda- mental Principles and Exploitation in Life Study and Health Care. New York: Nova Biomedical Books.
[11]	Rumyantsev S.N., Shabalow N.P., Pyasetskaya M.F., Rogacheva N.M., Bardakova L.I. (2000) Species, popu- lation and age diversity in cell resistance to adhesion of Neisseria meningitidis serogroups A, B and C. Microbes and Infection, 2, 447-453.
[12]	Bonnicksen A.L. (2009) Chimeras, hybrids, and inter- species research : politics and policymaking. Georgetown University Press, Washington, D.C.
[13]	McLaren A. (1976) Mammalian chimaeras. Cambridge University Press, Cambridge.
[14]	Rumyantsev S.N. (2006) The origin of individual differ- rences in the course and severity of diseases. The Scientific World Journal, 6, 1674-1704.
[15]	Rumyantsev S.N., Gerasimov V.K. (2007) The origin and functions of biodiversity in infectious and non-infectious diseases. In: Schwartz J. Ed., Focus on Biodiversity Research. Nova Science Publishers ,:199-300.
[16]	Briasoulis E., Pavlidis N. (1997) Cancer of unknown primary origin. The Oncologist, 2, 142-152.
[17]	Soto A. M. and Sonnenschein C. (2004) The somatic mutation theory of cancer: growing problems with the paradigm? Bioessays, 26, 1097-1107.
[18]	Hemminki K., Li X. and Czene K. (2004) Familial risk of cancer: data for clinical counseling and cancer gene- tics. Int J Cancer, 108, 109-114.
[19]	Ponz De Leon M. (1994) Familial and hereditary tumors. Springer, Berlin.
[20]	Hereditary Tumor. From Genes to Clinical Consequences. Wiley-VCH , 2008.
[21]	Hodgson H. (2008) Mechanisms of inherited cancer susceptibility. J Zhejiang University Sci B, 9, 1-4.
[22]	Jain R.V., Mills P.K. and Parikh-Patel A. (2005) Cancer incidence in the south Asian population of California, 1988-2000. J Carcinog, 4.
[23]	Yancy H.F., Mason J.A., Peters S, Thompson C.E., Litt- leton G.K., Jett M. and Day A.A. (2007) Metastatic pro- gression and gene expression between breast cancer cell lines from African American and Caucasian women. J Carcinog, 6.
[24]	Mardis E.R., Ding L., Dooling D.J., et al. (2009)361(11):-66.Recurring mutations found by se- quencing an acute myeloid leukemia genome. N Engl J Med, 361, 1058-1066.
[25]	Bernards R. and Weinberg R. A. (2002) Progression pu- zzle. Nature, 418, 823.
[26]	Liotta L.A. and Kohn E. C. (2003) Cancer's deadly sig- nature. Nature Genet, 33, 10-11.
[27]	Weigelt B., van't Veer L. J. (2004) Hard-wired genotype in metastatic breast cancer. Cell Cycle, 3, 756-757.
[28]	Podsypanina K., Li Y., Varmus H.E. (2004) Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype. BMC Med, 15, 24.
[29]	Podsypanina K., Du Y.C., Jechlinger M., Beverly L.J., Hambardzumyan D., Varmus H. (2008) Seeding and propagation of untransformed mouse mammary cells in the lung. Science, 321, 1841-1844.
[30]	Murchison E.P. (2008) Clonally transmissible cancers in dogs and Tasmanian devils. Oncogene, 27, S19-S30.
[31]	McAloose D., Newton A.L. (2009) Wildlife cancer: a conservation perspective. Nat Rev Cancer, 9, 517-526.
[32]	Welsh J.S. (2011) Contagious cancer. Oncologist, 16, 1-4.
[33]	Thompson M.S.and Mok S.C. (2009) Immunopatho- genesis of ovarian cancer. Minerva Med, 100, 357-370.
[34]	Torres M.P., Ponnusamy M.P., Lakshmanan I., Batra S.K. (2009) Immunopathogenesis of ovarian cancer. Minerva Med, 100, 385-400.
[35]	Rumyantsev S.N. (2010) Hypothesis: Towards the origin of cancer epidemics and pathogenesis. Journal of Carcinogenesis, 9, 1-7.
[36]	Boyd W.C. (1966) Fundamentals of immunology. Inter- science publishers, New York.
[37]	Haldane J.B.S. (1949) Disease and evolution . La Riserca Sci, 19S, 68-76.
[38]	Rumyantsev S.N. (1992) Observations on constitutional resistance to infection. Immunology Today, 13, 184-187.
[39]	Rumyantsev S.N. (1998) Constitutional and non-specific immunity to infection. Rev Sci Tech Off Int Epiz, 17, 26-42.
[40]	Friedman J.M. (2004) Modern science versus the stigma of obesity. Nature Medicine, 10, 563-569.
[41]	Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA, Cheetham CH, O'Rahilly S. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387:903-908.
[42]	Stunkard AJ, Harris JR, Pedersen NL, McClean GE. The body-mass index of twins who have been reared apart . N Engl J Med 1990;322:1483-1487.
[43]	Rumyantsev SN. Obesity: a reckoning both for genetic immunity to infection and xenogamy. Medical Hypothesis 2006;66:535-540.
[44]	Wan W, Farboud B, Privalsky ML. Pituitary resistance to thyroid hormone (RTH)-syndrome is associated with T3 receptor mutants that selectively impair{beta}2 isoform function . Mol Endocrinol 2005;19:1529-1542.
[45]	Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J. Cancer Incidence in Five Continents. Lyon France, World Health Organization , 1992.
[46]	Lockhart-Mummery JP. A Paper on The origin of tumors. Br Med J 1932;1:785-787.
[47]	Chaffer CL, Weinberg RA. A Perspective on Cancer Cell Metastasis. Science 2011;331:1559-1564 .
[48]	Jiao X, Krasna MJ. Clinical significance of micrometastasis in lung and esophageal cancer: a new paradigm in thoracic oncology. Ann Thorac Surg 2002;74:278-284.
[49]	Pantel K, Otte M. Occult micrometastasis: enrichment, identification and characterization of single disseminated tumour cells. Semin Cancer Biol 2001; 11:327-337.
[50]	Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 1999;91:80-85.
[51]	Sahai E. Illuminating the metastatic process. Nat Rev Cancer 2007;7:737-749.
[52]	Rumyantsev SN. The Discredit of Cancer Metastasis. Science Advisory Board [http://www.scienceboard.net/community/perspectives.227.html], 2009.
[53]	Rumyantsev SN. The Uniqueness and Ordinariness of Cancer Origin and Pathogenesis: New Epidemiological, Clinical and Preventive Perspectives. J Clin Med Res 2009;1:32-36.
[54]	Pockaj BA, Wasif N, Dueck AC, Wigle DA, Boughey JC, Degnim AC, Gray RJ, McLaughlin SA, Northfelt DW, Sticca RP, Jakub JW, Perez EA. Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look? Ann Surg Oncol 2010;17:2419-2426.
[55]	Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011;305:569-575.
[56]	Hanin L, Korosteleva O. Does extirpation of the primary breast tumor give boost to growth of metastases? Evidence revealed by mathematical modeling. Math Biosci 2010;223:133-141.
[57]	Sorin V, Mizrahi A, Ohana P, Ayesh S, Birman T, Hochberg A, Czerniak A. Partial Hepatectomy in rats results in significant growth of liver metastases by increased expression of H19 gene. Cancer Therapy 2009;7:240-244.
[58]	de Jong KP, Lont HE, Bijma AM, Brouwers MA, de Vries EG, van Veen ML, Marquet RL, Slooff MJ, Terpstra OT. The effect of partial hepatectomy on tumor growth in rats: in vivo and in vitro studies. Hepatology 1995;22:1263-1272.
[59]	Garcia-Alonso I, Palomares T, Alonso A, Portugal V, Castro B, Carames J, Mendez J. Effect of hepatic resection on development of liver metastasis. Rev Esp Enferm Dig 2003;95:765-767.
[60]	Ikeda Y, Matsumata T, Takenaka K, Sasaki O, Soejima K, Sugimachi K. Preliminary report of tumor metastasis during liver regeneration after hepatic resection in rats. Eur J Surg Oncol 1995;21:188-190.
[61]	Elias D, De Baere T, Roche A, Ducreux M, Leclere J, Lasser P. During liver regeneration following right portal embolization growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 1999;86:784-788.
[62]	von Schweinitz D, Fuchs J, Gluer S, Pietsch T. The occurrence of liver growth factor in hepatoblastoma. Eur J Pediatr Surg 1998;8:133-136.
[63]	American Cancer Society. . Cancer Facts & Figures 2009. Atlanta: American Cancer Society, 2009.
[64]	Levi F, Randimbison L, Te VC, Conconi MM, La Vecchia C. Risk of prostate, breast and colorectal cancer after skin cancer diagnosis. Int JCancer 2008;123:2899-3001.
[65]	Milan T, Pukkala E, Verkasalo PK, Kaprio J, Jansen CT, Koskenvuo M, Teppo L. Subsequent primary cancers after basal-cell carcinoma: a nationwide study in Finland from 1953 to 1995. Int J Cancer 2000;87:283-288.
[66]	Nugent Z, Demers AA, Wiseman MC, Mihalcioiu C, Kliewer EV. Risk of second primary cancer and death following a diagnosis of nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 2584- 2590.
[67]	Soerjomataram I, Louwman WJ, Lemmens VE, Coebergh JW, de Vries E. Are patients with skin cancer at lower risk of developing colorectal or breast cancer? Am J Epidemiol 2008;167:1421-1429.
[68]	Soerjomataram I, Coebergh JW. Epidemiology of multiple primary cancers. Methods Mol Biol 2009;471: 85-105.
[69]	Rumyantsev SN. The intra-individual diversity in senescence. Biogerontology 2003;4:171-178.
[70]	Patterson N, Richter DJ, Gnerre S, et al. Genetic evidence for complex speciation of humans and chimpanzees. Nature 2006;441:1103-1108.
[71]	Soficaru A, Dobos A, Trinkaus E. Early modern humans from the Pestera Muierii, Baia de Fier, Romania. Proc Natl Acad Sci U S A 2006;103:17196-17201.
[72]	Rumyantsev SN. Bioecology of pleistocenic spurt in anthropogenesis. Int J Integ Biol 2010;10:14-21.